ArticleBMC biotechnology2025
Mycosynthesis of silver nanoparticles by Aspergillus templicola OR480102: a multifaceted approach for antibacterial, anticancer, and scratch assay applications.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Who Reduces Silver? A Critical Review of the Biomolecular Drivers of Fungal-Mediated Silver Nanoparticle Biosynthesis.International journal of molecular sciences · 2026Review
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Silver Nanoparticles in Antibacterial Research: Mechanisms, Applications, and Emerging Perspectives.International journal of molecular sciences · 2026Review
- Biosynthesis of silver nanoparticles using Phoma herbarum and evaluation of their fungicidal effects against onion basal root rot disease.BMC biotechnology · 2025Article
- Microbial-Based Green Synthesis of Silver Nanoparticles: A Comparative Review of Bacteria- and Fungi-Mediated Approaches.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegarding their distinct physico-chemical and bioactivity characteristics, silver nanoparticles 'AgNPs' are extensively utilized in numerous scientific purposes.
resultsWithin this current investigation, for the first time, we evaluated how the extracellular extract of the isolate MAK223 generated exceptionally fixed AgNPs. The isolate was genetically identified as Aspergillus templicola OR480102. The generated AgNPs' physico-chemical characteristics were assessed using ultraviolet-vis spectroscopy, transmission electron microscopy (TEM), and Fourier transform infrared spectrometry (FT-IR). The maximum absorption in the UV-vis spectrum was obtained at 420 nm, matching the silver nanoparticles' surface plasmon absorbance. A. templicola OR480102 produced uniformly dispersed AgNPs between 5 and 25 nm with a mean dimension of 17.78537 ± 1.36 nm using TEM. FT-IR analysis identified functional groups (e.g., -OH, C = O) in the fungal filtrate that mediate AgNP synthesis and capping. To verify AgNPs stability, the dynamic light scattering (DLS) approach is employed. Optimal conditions for AgNPs synthesis were 10 days of incubation, one mM silver nitrate concentration, pH 11, and elevated temperatures. AgNPs demonstrated efficacy against clinically relevant pathogens: S. typhimurium 'ATCC 14028', B. subtilis 'ATCC 6633', S. aureus 'ATCC 25923', and E. coli 'ATCC 29213' were used in the study. Also, using AgNPs derived from the filtrate of A. templicola OR480102 shows significant potential as a novel therapeutic approach against breast cancer cells 'MCF-7'. The scratch assay of 'MCF-7' cells demonstrates the suppressive impact of AgNPs for these cell lines during proliferation by promoting apoptosis and reducing cell migration.
conclusionBased on physico-chemical characteristics of AgNPs' and their antimicrobial and anticancer activities, it cleared that the selected strain Aspergillus templicola OR480102 is a promising producer of stable AgNPs' with significant bioactivities which could be applicable in different fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.